Value2021202220232024TTMSelling/general/admin expenses———26.88 M24.15 MResearch & development———67.88 M81.08 MOperating income———-63.32 M-82.97 MNon-Operating Income, Total———5.12 M4.63 MInterest expense, net of interest capitalized—————Non-Operating Income, excl. Interest Expenses———646 K993 KUnusual income/expense———4.47 M3.64 MPretax income———-44.46 M-64.2 MEquity in earnings—————Taxes———845 K335 KNon-controlling/minority interest—————After tax other income/expense—————Net income before discontinued operations———-45.31 M-64.54 MDiscontinued operations—————Net income———-45.31 M-64.54 MDilution adjustment—————Preferred dividends—————Diluted net income available to common stockholders———45.31 M64.54 MBasic earnings per share (Basic EPS)———-0.33-0.46Diluted earnings per share (Diluted EPS)———-0.33-0.46Average basic shares outstanding———138.75 M563.81 MDiluted shares outstanding———138.75 M563.81 MEBITDA———5.12 M-1.34 MEBIT———4.56 M-1.89 MCost of revenue———11.81 M2.24 MOther cost of goods sold—————Depreciation & amortization (cash flow)———557 K546 K
Silence Therapeutics Plc - American Depository Share
Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.